Having trouble accessing articles? Reset your cache.

Early success in GvHD sets up NDA for Kadmon’s lead

With its lead clinical candidate meeting the primary endpoint at an interim analysis of a pivotal trial for third-line chronic graft-versus-host disease, Kadmon plans to submit an NDA next year for KD025

Read the full word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers